Domenico Cicala

Dr. Domenico Cicala

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2013 in MUSCULOSKELETAL SURGERY
Verified
Journal Article
Closed access
PDF file
DCDomenico Cicala
Domenico Cicala
FBF. Briganti
F. Briganti
LCL. Casale
L. Casale
CRC. Rossi
C. Rossi
LCLucio Cagini
Lucio Cagini
MGM. Giganti
M. Giganti

3 May 2016 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
O(On behalf of the European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy)
On behalf of the European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy)
CDC. De Divitiis
C. De Divitiis
CAClaudia von Arx
Claudia von Arx
AGA. M. Grimaldi
A. M. Grimaldi
DCDomenico Cicala
Domenico Cicala
STSalvatore Tafuto
Salvatore Tafuto
Neuroendocrine Neoplasms (NEN) are a group of heterogeneous malignancies derived from neuroendocrine cell compartment, with different roles in both endocrine and nervous system. Most NETs have gastroentero-pancreatic (GEP) origin, arising in the foregut, midgut, or hindgut. The 2010 WHO classification divides GEP-NETs into two main subgroups, neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), according with Ki-67 levels. NET are tumors with low (20 %–G3). Poorly differentiated neuroendocrine carcinomas (NEC) are usually treated with cisplatin-based chemotherapy regimens. Here we present a case of a patient with pancreatic NEC progressing after cisplatin and etoposide, treated with temozolomide as palliative, second line treatment. According with the poor Performance Status (PS = 2) and to reduce the toxicity of the treatment was chosen an intermittent dosing regimen of metronomic temozolomide (75 mg/m2/day—one-week-on/on-week-off). MGMT resulted methylated. On July 2014 the patient started the treatment. On August 2014 the patient obtained a significant clinical benefit (PS = 0) and the total body CT scan performed on October 2014 showed a RECIST partial response on all the sites of disease. No drug-related side effects were reported by the patient. After 18 months of therapy the treatment continues without significant toxicity, and with further remission of the metastases. Treatment with metronomic “one-week-on/on-week-off” Temozolomide can be considered a good treatment option in patients with poor performance status, affected by pNEC with MGMT methylation.

Verified
Journal Article
Open access
PDF file
CSClaudia Santoro
Claudia Santoro
GMGiuseppe Mirone
Giuseppe Mirone
MZMariateresa Zanobio
Mariateresa Zanobio
GRGiusy Ranucci
Giusy Ranucci
ADAlessandra D’amico
Alessandra D’amico
Giulio PilusoGiulio Piluso
Giulio Piluso
Moyamoya angiopathy (MMA) is a rare cerebral vasculopathy in some cases occurring in children. Incidence is higher in East Asia, where the heterozygous p.Arg4810Lys variant in RNF213 (Mysterin) represents the major susceptibility factor. Rare variants in RNF213 have also been found in European MMA patients with incomplete penetrance and are today a recognized susceptibility factor for other cardiovascular disorders, from extracerebral artery stenosis to hypertension. By whole exome sequencing, we identified three rare and previously unreported missense variants of RNF213 in three children with early onset of bilateral MMA, and subsequently extended clinical and radiological investigations to their carrier relatives. Substitutions all involved highly conserved residues clustered in the C-terminal region of RNF213, mainly in the E3 ligase domain. Probands showed a de novo occurring variant, p.Phe4120Leu (family A), a maternally inherited heterozygous variant, p.Ser4118Cys (family B), and a novel heterozygous variant, p.Glu4867Lys, inherited from the mother, in whom it occurred de novo (family C). Patients from families A and C experienced transient hypertransaminasemia and stenosis of extracerebral arteries. Bilateral MMA was present in the proband’s carrier grandfather from family B. The proband from family C and her carrier mother both exhibited annular figurate erythema. Our data confirm that rare heterozygous variants in RNF213 cause MMA in Europeans as well as in East Asian populations, suggesting that substitutions close to positions 4118–4122 and 4867 of RNF213 could lead to a syndromic form of MMA showing elevated aminotransferases and extracerebral vascular involvement, with the possible association of peculiar skin manifestations.

23 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
CRCamilla Russo
Camilla Russo
FAFerdinando Aliberti
Ferdinando Aliberti
UFUrsula Pia Ferrara
Ursula Pia Ferrara
CRCarmela Russo
Carmela Russo
DGDomenico Vincenzo De Gennaro
Domenico Vincenzo De Gennaro
giuseppe cinalligiuseppe cinalli
giuseppe cinalli
Craniosynostoses (CRS) are caused by the premature fusion of one or more cranial sutures, with isolated nonsyndromic CRS accounting for most of the clinical manifestations. Such premature suture fusion impacts both skull and brain morphology and involves regions far beyond the immediate area of fusion. The combined use of different neuroimaging tools allows for an accurate depiction of the most prominent clinical–radiological features in nonsyndromic CRS but can also contribute to a deeper investigation of more subtle alterations in the underlying nervous tissue organization that may impact normal brain development. This review paper aims to provide a comprehensive framework for a better understanding of the present and future potential applications of neuroimaging techniques for evaluating nonsyndromic CRS, highlighting strategies for optimizing their use in clinical practice and offering an overview of the most relevant technological advancements in terms of diagnostic performance, radiation exposure, and cost-effectiveness.

29 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CRCamilla Russo
Camilla Russo
SCSimone Coluccino
Simone Coluccino
MLMaria Fulvia De Leva
Maria Fulvia De Leva
SGStefania Graziano
Stefania Graziano
CRCarmela Russo
Carmela Russo
ECEugenio Maria COVELLI
Eugenio Maria COVELLI
Background: Cortical tubers (CTs) are hallmark brain lesions in tuberous sclerosis complex (TSC), historically considered stable in number over time; prior literature has correlated overall CT burden on magnetic resonance imaging (MRI) with disease severity. As longitudinal imaging studies assessing CTs’ evolution over time are lacking, we aim to investigate temporal changes in CTs—both in number and signal—on MRI in a cohort of pediatric TSC patients. Methods: A retrospective single-center analysis was conducted on 57 pediatric TSC patients who underwent longitudinal MRI studies in a 10-year span. Required MRI sequences included volumetric unenhanced T1-weighted, SWI, T2w and/or FLAIR. CTs were evaluated by two neuroradiologists and classified into five subtypes (A, B, C1, C2, D) according to signal characteristics. Statistical comparison was performed using t-tests. Results: Paired t-test analysis demonstrated a significant longitudinal increase in the overall number of CTs, rising from 16.11 ± 12.43 at baseline to 18.77 ± 13.29 at follow-up (mean difference = −2.67, 95% CI [−3.94, −1.39]; t (56) = 4.19; p < 0.0001), corresponding to a moderate effect size (Cohen’s d ≈ 0.56). When stratified by age, patients <2 years—representing the incompletely myelinated subgroup—showed a more pronounced increase in CT burden, from 19.46 ± 15.21 to 24.17 ± 15.75 (mean difference = −4.71, 95% CI [−7.37, −2.04]; t (23) = 3.65; p = 0.0013; d ≈ 0.75). In contrast, patients aged ≥2 years demonstrated a smaller but still significant increase, from 13.67 ± 9.45 to 14.85 ± 9.64 (mean difference = −1.18, 95% CI [−2.08, −0.28]; t (32) = 2.68; p = 0.0115; d ≈ 0.46). Direct comparison between the two subgroups using Welch’s two-sample t-test confirmed that the mean CT count in patients <2 years was significantly higher than in those ≥2 years (mean difference = 3.53 ± 1.36; t = 2.59; df = 28.4; p = 0.0075), with a large effect size (Cohen’s d ≈ 0.78). Type C1-C2 tubers evolved from pre-existing earlier-stage lesions, while most newly visible CTs over time were type A-B. Type D tubers remained rare and derived from earlier-stage CTs. Conclusions: Contrary to previous assumptions, CTs in pediatric TSC showed a tendency to increase in number and evolve in signal over time, thus challenging the notion of stability and suggesting dynamic behavior. Incomplete myelination in early infancy may impact MRI CTs detection by reducing contrast with surrounding brain tissue, potentially leading to their underestimation/misidentification.

1 January 2015
Verified
Book Chapter
Closed access
PDF file
DCDaniele Cascone
Daniele Cascone
MPMaria Rita Panico
Maria Rita Panico
MBMaria Consiglio Buonocore
Maria Consiglio Buonocore
DCDomenico Cicala
Domenico Cicala
ANAnna Nastro
Anna Nastro
ECEmilio Cianciulli
Emilio Cianciulli